FDA approves Toviaz to treat overactive bladder condition

WASHINGTON The Food and Drug Administration has approved a new drug by Pfizer for treating overactive bladder, the agency announced Friday.

Toviaz (fesoterodine fumarate) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate and sudden incontinence associated with overactive bladder.

“Patients who suffer from overactive bladder face quality of life issues that can hamper their ability to enjoy life to its fullest,” said George Benson, deputy director of the reproductive and urologic drugs division of the FDA’s Center for Drug Evaluation and Research. “This new drug will provide an additional treatment option to help them manage problems with an overactive bladder.”